#SYNCHN2026 Panel: Accelerating Early Clinical Translation: From Discovery to First in Human and Advanced Therapeutics Industry and regulatory leaders shared key imperatives to build a self-reliant, world-class innovation pipeline in India: Dr. A. Visala (Joint DCGI): 'Robust data documentation and integrity is the key aspect that the regulator looks for. The R&D ecosystem must value this.' @CDSCO_INDIA_INF Dr. Roli Mathur (ICMR): 'Ethics should not be restricted only to getting the approvals but must form part of the research project from the start.' @Mathur_Roli @ICMRDELHI Dr. Raches Ella (Bharat Biotech): 'Pre-defined roadmaps will help bridge academia and industry, backed by the confidence of institutions like THSTI's biofoundry.' @BharatBiotech Dr. Sachin Kale (Serum Institute): 'We value innovators willing to work with us throughout the product life cycle to troubleshoot process and analytical challenges.' @SerumInstIndia Dr. Jaideep Gogtay (Cipla): 'Involving the civil society is important for successful translation to address massive public health burdens like chronic lung diseases.' @Cipla_Global Prof Vikram Mathews (CMC Vellore): 'High-quality science should continue to be supported for its scientific merit, recognizing that the innovation life cycle is often long.' @MathewsVikram @OffCMCVellore Prof. Meta Roestenberg (Infecta): 'I urge researchers to embrace innovation and uncertainty and not necessarily copy and do what the West has been doing.' @UniLeiden Dr. Natrajan (Miltenyi Biotech): 'For disruptive innovation to succeed, it needs to be adopted at scale. Innovation is no longer an option, it is a necessity.' @miltenyibiotec #TranslationalResearch #HealthcareInnovation #PublicHealth @DBTIndia @BricDbt @rajesh_gokhale @drkarthik2010